Grail (NASDAQ: GRAL), which was spun off from Illumina (NASDAQ: ILMN) in 2024, reached a record high of $116.06 on Jan. 22. But today, the cancer test developer's stock trades at just under $70. Is it a buy, sell, or hold at these levels?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Grail's Galleri blood test aims to detect signals from dozens of cancers before any symptoms appear. That seems like a game changer for the oncology market, but its stock plunged in February after its largest NHS England trial failed to meet its primary endpoint. That trial was considered a crucial stepping stone toward an FDA approval in the U.S. -- which would clear the way for private insurance and Medicare plans to cover its tests.
However, Grail already sells Galleri on a cash-only basis (for $749 to $949) to independent customers, select employers, hospital pilots, and telehealth programs. Its NHS England trial also wasn't a complete failure: Galleri's users in the trial still had fewer Stage IV cancers detected, and it achieved earlier (Stage I and II) detection of the deadliest cancers.
Even without a near-term FDA approval, ******* ysts expect Grail's revenue to grow from $147 million in 2025 to $281 million in 2028. It won't generate a profit anytime soon, and its stock isn't cheap at 17 times this year's sales, but an FDA approval could help it crush those estimates. Therefore, I think it's smarter to buy and hold Grail at under $70 than to hastily sell it.

#grail #cancers #galleri

Pfizer Inc. (NYSE:PFE) is one of the 8 Worst Blue Chip Stocks to Buy Now.
On July 10, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for adult patients with muscle-invasive bladder cancer, regardless of cisplatin eligibility. Pfizer said this marks the first platinum-free regimen approved for adult patients with MIBC, regardless of cisplatin eligibility.
The approval was based on results from the pivotal Phase 3 EV-304 clinical trial, which were presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium. The expanded indication builds on the November 2025 U.S. FDA approval of the combination for use as neoadjuvant and adjuvant treatment in cisplatin-ineligible adult patients with MIBC, based on results from the EV-303 Phase 3 clinical trial published in the New England Journal of Medicine.
Also on July 10, BofA lowered the firm's price target on Pfizer to $26 from $27 and kept a Neutral rating on the shares. On July 6, HSBC downgraded Pfizer to Hold from Buy with a price target of $28, down from $32. HSBC lowered its view of the probability to market of sigvotatug vedotin to 40% following the Phase 3 setback in NSCLC and said it is now "less convinced" regarding short-term re-rating potential due to recent executive management changes and "a paucity of short-term re-rating catalysts."
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Harris Oakmark recently released its second-quarter 2026 investor letter for the "Oakmark Global Fund". A copy of the letter can be downloaded here. It is a non-diversified fund that focuses on long-term capital appreciation by investing in common stocks of U.S. and non-U.S. companies. In the second quarter, the fund (Investor Class) delivered a return of 7.89%, lagging the benchmark, the MSCI World Index's 13.76% return. Energy and industrials were the top performance contributors at the sector level, while health care and consumer discretionary detracted from performance. AI remains a key market theme. The firm focuses on evaluating companies based on their competitive advantages, long-term cash flow potential, and valuation, not predictions. In addition, you can check the Fund's top five holdings to determine its best picks for 2026.
In its Q2 2026 investor letter, Oakmark Global Fund highlighted AstraZeneca PLC (NYSE:AZN) as a newly added position. AstraZeneca PLC (NYSE:AZN) is a leading multinational biopharmaceutical company focusing on the development and discovery of prescription medicines. On July 15, 2026, AstraZeneca PLC (NYSE:AZN) closed at $168.37 per share, reflecting a market capitalization of $261.12 billion. AstraZeneca PLC (NYSE:AZN) posted a one-month return of -3.75%, while its shares gained 18.55% over the past 52 weeks.
Oakmark Global Fund stated the following regarding AstraZeneca PLC (NYSE:AZN) in its Q2 2026 investor update:
"AstraZeneca PLC (NYSE:AZN) is one of the largest pharmaceutical companies in the world. It researches, develops and commercializes prescription medicines designed to treat lung and breast cancers, cardiorenal diseases, respiratory problems and other rare diseases. We believe AstraZeneca's robust on-market portfolio and sector-leading late-stage pipeline provide an attractive growth profile. Moreover, we believe the company can build on its long track record of a productive research and development program, thanks to its innovative culture and exceptional management team. In our view, CEO Pascal Soriot is one of the industry's best executives, and he has cultivated a deep bench of talent, a robust decision-making framework and a differentiated R&D culture that should drive strong growth for years to come, in our view. Recent concerns over United States regulations have overshadowed AstraZeneca's merits and weighed on the broader pharmaceutical industry. This opened a window for us to purchase shares of this company at a price well below our estimate of its intrinsic value."

(NewsNation) — Your gut bacteria may influence hormone-related cancer risk, researchers say.
The bacteria living in your gut may play a much larger role in hormone-related cancers than scientists previously believed, according to a new review published in the journal npj Biofilms and Microbiomes.
Researchers ***** yzed existing studies examining how the gut microbiome — the trillions of bacteria and other microbes that live in the digestive tract — interacts with the body's hormone system.
While scientists have long known gut bacteria help regulate estrogen, the review suggests the microbiome acts as an active partner in hormone signaling, influencing inflammation, metabolism and immune responses that may affect cancer development.
New protein controls how the body stores, burns fat: study

Summer Pardi revealed her father's cancer diagnosis less than 24 hours before she and her husband, country singer Jon Pardi, announced their plans to divorce
Her father, Larry Duncan, was diagnosed with multiple myeloma, a blood cancer that also affects the bones
Summer and Jon were married for five years and share two young daughters
Less than 24 hours before Jon and Summer Pardi announced their divorce, Summer shared that her father was diagnosed with cancer.
"A little life update on my dad.. i know everyone on here loves him dearly, even those who don't know him personally. He's a special guy and he's gonna kick cancers ***** ," she wrote under a post shared to her Instagram Stories on Thursday, July 2.

A new drug, decades in the making, is showing game-changing results for those battling pancreatic cancer. NBC’s medical contributor Dr. Natalie Azar joins TODAY with what you need to know about the breakthrough medication that doubled survival time and slowed tumor progression in patients during trials and how it could potentially help treat other cancers.

Researchers have developed nasal drops that travel along the nerves of the nose into the central nervous system to fight the deadliest brain cancer.
Preliminary test results reveal that the medication safely reached its target, helping protect mice against these usually fatal tumors.
"This is an approach that offers hope for safer, more effective treatments for glioblastoma and potentially other immune treatment-resistant cancers, and it marks a critical step toward clinical application," says neurosurgeon Alexander Stegh of Washington University.
"This redefines how cancer immunotherapy ca

Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025 http://dlvr.it/TKx42n

http://dlvr.it/TKx42n